Hypertension, BMI, and cardiovascular and cerebrovascular diseases

Abstract: Hypertension is associated with body mass index (BMI) and cardiovascular and cerebrovascular diseases (CCDs). Whether hypertension modifies the relationship between BMI and CCDs is still unclear. We examined the association between BMI and CCDs and tested whether effect measure modification was present by hypertension. We identified a population-based sample of 3,942 participants in Shuncheng, Fushun, Liaoning, China. Hypertension was defined as any past use of antihypertensive medication or having a measured systolic/diastolic blood pressure $\geq$130/80 mm Hg. BMI was calculated from measured body weight and body height. Data on diagnosed CCDs were self-reported and validated in the medical records. We used logistic regression models to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between BMI and CCDs. Higher BMI was associated with increased odds of having CCDs (OR = 1.19, 95% CI: 1.07–1.31). This association was significantly modified by hypertension ($P$ for interaction <0.001), with positive associations observed among hypertensive individuals (OR = 1.28, 95% CI: 1.14–1.42). Age, sex, and diabetic status did not modify the relationship between BMI and CCDs (all $P$ for interaction >0.10). Although higher BMI was associated with increased odds of CCDs, the relationship was mainly limited to hypertensive patients.

Keywords: cardiovascular and cerebrovascular diseases, body mass index, hypertension

1 Introduction

Cardiovascular and cerebrovascular diseases (CCDs) are major public health problems worldwide [1–4], with 121.5 million individuals suffering from cardiovascular disease and $\sim$10.3 million new stroke cases during 2016 [5]. The incidence of CCDs is predicted to triple over the next few decades [6]. Stroke and ischemic heart disease were the top two causes for years of life lost globally in 2013 [7]. The total cost for hospitalization of acute myocardial infarction and stroke was 905.3 billion RMB (approximately US $137.4 billion) in 2016 [5]. In 2016, the number of deaths related to CCDs reached 17.9 million, accounting for 31% of all deaths worldwide [8].

It is well documented that higher body mass index (BMI) is associated with higher risk of CCDs [9]. Whether the relationship is modified by hypertensive status is unknown. For individuals with BMI $\geq$25 kg/m$^2$, each 5 kg/m$^2$ increase in BMI was associated with 40% higher risk of CCDs [9]. In addition, BMI is positively correlated with blood pressure [10]. For every 3 kg/m$^2$ increase in BMI, the risk of hypertension increases by 50% in men and 57% in women [11]. Individuals with a BMI $\geq$ 24 kg/m$^2$ have 3–4 times the risk of hypertension compared to individuals with a normal BMI in the general population [12]. Meanwhile, a prospective study in a Chinese population reported that for every 10 and 5 mm Hg increase in systolic blood pressure (SBP) and diastolic blood pressure (DBP), respectively, the risk of CCDs increased by 49 and 46% [13].

Hypertension may modify the association between BMI and CCDs, but there are few studies that have examined this [14,15]. Therefore, the present study sought to (1) examine the relationship between BMI and CCDs and

* Corresponding author: Shuman Yang, Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, 232-1163 Xinmin Street, Changchun, 130021, Jilin, China, e-mail: shumanyang@jlu.edu.cn, tel: +86-18043635263, fax: +86-043185645486

Wenjing Qiao, Shanshan Xue, Yuzheng Zhang, Binbin Li, Qianqian Zhao, Dingjie Guo, Xue Shen, Shuman Yang*

School of Epidemiology and Biostatistics, School of Public Health, Jilin University, 232-1163 Xinmin Street, Changchun, 130021, Jilin, China

Xinyi Zhang: Department of Noninfectious Chronic Diseases Control, Disease Prevention and Control Center, Fushun, Liaoning, China

Bo Kan: Department of Clinical Laboratory, The Bethune Second Affiliated Hospital, Jilin University, Changchun, Jilin, China

Ann M. Vuong: Department of Epidemiology and Biostatistics, School of Public Health, University of Nevada, Las Vegas, United States of America

https://doi.org/10.1515/med-2021-0014

received May 15, 2020; accepted November 6, 2020
(2) determine whether this relationship is modified by hypertensive status.

2 Materials and methods

2.1 Study population

Using a random sampling method, this cross-sectional study enrolled 4,553 population-based residents in Shuncheng, Fushun, Liaoning, China from 2013 to 2016. Shuncheng is a district located in northern Fushun, a northeastern city in China approximately 742 km away from Beijing. The area of Shuncheng is 348 km², with a population of ~0.4 million. This study randomly selected eight regions in Shuncheng and distributed 600 questionnaires in each region, totaling 4,800 questionnaires. Written informed consent was obtained from all participants before study enrollment. Among 4,800 returned questionnaires, 247 were excluded from the study because they were incomplete or failed to meet our quality control standards following an assessment. Although the response rate was 100%, we were only able to use 94.9% of the returned questionnaires. All data were fully anonymized before analyses. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Centers for Disease Control (CDC) of Fushun.

For the present study, we included all participants aged 18 years or older. We excluded individuals with missing or invalid data on body weight, height, status of CCDs, age, and sex.

2.2 Study measures

Our primary outcome was CCDs, which included cardiovascular diseases (e.g., coronary heart disease, angina, etc.) and cerebrovascular diseases (e.g., cerebral hemorrhage, cerebral thrombosis, etc.). CCDs were further categorized into cardiovascular diseases and cerebrovascular diseases. Information for CCDs was obtained via self-reported questionnaire inquiring whether they were ever diagnosed by specialists from government-funded hospitals. We also validated all reported diagnoses of CCDs based on their medical records.

The covariates for this study included age, body weight, body height, sex, hypertensive status, smoking, alcohol use, and diabetic status. Body weight, without shoes, was measured (to the nearest 0.1 kg) on an electronic scale. Body height, without shoes and in light clothing, was measured to the nearest 0.1 cm by a wall-mounted stadiometer. BMI was calculated using: body weight (kg) divided by body height squared (m²). The subjects were classified into the following categories according to their BMI: non-obese (<28 kg/m²) and obese (≥28 kg/m²); this classification was based on the 2002 recommendations of the CDC, China [16,17]. Each participant had his/her blood pressure measured after a period of rest of 5 min. SBP and DBP were measured with an automated sphygmomanometer thrice. Investigators asked each participant whether he/she had taken any antihypertensive medications. Hypertension was defined as any past use of antihypertensive medication or having a measured SBP/DBP ≥130/80 mm Hg based on the guidelines released by the American College of Cardiology/American Heart Association (ACC/AHA) [18]. For our sensitivity analysis, we also defined hypertension as past antihypertensive medication use or SBP/DBP ≥140/90 mm Hg [19]. Fasting blood glucose was measured using a portable blood glucose meter. Diabetic status was defined as having a fasting blood glucose >7.1 mmol/L (http://www.diabetes.org/diabetes-basics/diagnosis/). A structured questionnaire was used to obtain sociodemographics as well as lifestyle and behavioral characteristics. Smoking was defined as current tobacco use. Individuals were classified as alcohol users if he/she reported a history of alcohol intake within the past 12 months.

2.3 Statistical analysis

In the descriptive analysis, continuous variables with a normal distribution are shown as means and standard deviations (SDs) and categorical variables were expressed as frequencies and percentages. The baseline characteristics of participants with and without CCDs were compared using independent t-test and chi-square test.

We used logistic regression models to estimate covariate-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for BMI (per SD increase) and CCDs. This model adjusted for age (continuous), sex (male/female), hypertensive status (yes/no), smoking (yes/no), alcohol use (yes/no), and diabetic status (yes/no). These covariates were selected a priori based on a literature review of the relationship between BMI and CCDs [5,8,20,21]. We further tested whether effect measure modification was
present between BMI (per SD increase) and CCDs by the following variables: (1) age (≤50, >50), (2) sex (male/female), (3) diabetic status (yes/no), and (4) hypertension (yes/no). To do this, we built interaction terms between BMI and each variable in the logistic regression models. Interaction was considered to be present if the P-value was <0.05. All statistical analyses were performed using SPSS software (version: 24.0; SPSS, Chicago, IL, USA).

3 Results

Of the 4,553 individuals recruited, 3,942 individuals met our inclusion and exclusion criteria and were included in the present study (Figure 1). Average age of our study population was 48.9 years (SD = 15.9 years). There were 385 (9.8%) individuals with CCDs (Supplemental Table S1). Individuals with CCDs had significantly higher BMI, were older, more likely to be females, hypertensive (based on both hypertensive cut-points), and diabetic individuals (Table 1). The prevalence of hypertension based on a blood pressure of ≥130/80 and ≥140/90 mm Hg was 64.5 and 23.7%, respectively, in the overall study population. Smoking, alcohol use, and diabetes were observed in 24.0, 26.6, and 4.4% of the 3,942 study participants, respectively.

After adjusting for covariates, a SD increase in BMI was associated with greater odds of having hypertension (≥130/80 mm Hg) (OR = 1.50, 95% CI: 1.38–1.64, Figure 2) and CCDs (OR = 1.19, 95% CI: 1.07–1.31). Hypertension (≥130/80 mm Hg) was associated with increased odds of CCDs (OR = 1.46, 95% CI: 1.10–1.93). Similar associations were noted when we further explored the relationship between BMI, hypertension (≥130/80 mm Hg), and cardiovascular diseases (Supplemental Figure S1) and cerebrovascular diseases (Supplemental Figure S2). Specifically, a SD increase in BMI was associated with increased odds of cardiovascular diseases (OR = 1.20, 95% CI: 1.07–1.34) but not with cerebrovascular diseases (OR = 1.03, 95% CI: 0.79–1.35) (Supplemental Table S2). Among individuals with BMI ≥28 kg/m² and hypertension (≥130/80 mm Hg), the point estimate suggests a potential stronger relationship with CCDs than among individuals with a BMI <28 kg/m² (Supplemental Table S3).

Significant effect measure modification by hypertension (≥130/80 mm Hg) was noted in the relationship between BMI and CCDs (P for interaction <0.001) (Table 2). The significant positive association between BMI and CCDs was only observed among individuals with hypertension (≥130/80 mm Hg) (OR = 1.28, 95% CI: 1.14–1.42) but not among non-hypertensive individuals (OR = 0.73, 95% CI: 0.55–0.99). Furthermore, findings indicate a
significant inverse relationship between BMI and CCDs among non-hypertensive individuals. However, when hypertensive status was diagnosed as blood pressure \( \geq 140/90 \) mm Hg, the interaction term between BMI and hypertension failed to reach statistical significance \( (P \text{ for interaction} = 0.575) \). We did not observe interaction by age, sex, or diabetic status in the relationship between BMI and CCDs (all \( P \text{ for interaction} > 0.10 \)).

### 4 Discussion

In this cross-sectional study, we found a significant positive relationship between BMI and CCDs. Interestingly, the positive relationship between BMI and CCDs was only found among hypertensive individuals (blood pressure \( \geq 130/80 \) mm Hg). When hypertension was defined using \( \geq 140/90 \) mm Hg, no interaction was noted for hypertensive status in the relationship between BMI and CCDs. These results suggested that early intervention and management of hypertensive individuals (blood pressure \( \geq 130/80 \) mm Hg) with higher BMIs may be important to prevent CCD outcomes.

We found a significant association between BMI with cardiovascular disease but not with cerebrovascular disease. This is also in line with previous studies, in which BMI was more strongly associated with cardiovascular diseases than cerebrovascular diseases \([22–24]\). Huxley et al. and Barry et al. found that obesity was a risk factor for cardiovascular disease \([22,24]\), whereas Sun et al. reported that the risk of cerebrovascular disease was not significantly different between overweight, obese, and normal-weight individuals \([23]\).

In our study, we found that hypertension was more strongly associated with CCDs among obese individuals compared to non-obese people. These findings are consistent with previous studies \([25–27]\). As the baseline BMI level increases, individuals with hypertension have 2–3 times higher risk of CCDs than those with normal blood pressure \([25]\). It is likely that hypertension is an earlier predictor for CCDs among obese people.

We did not find significant interaction by age, sex, or diabetic in the association between BMI and CCDs. This is consistent with many previous studies, in which age, sex, and diabetes status were independent of BMI for assessing risk of CCDs \([28–30]\).

### Table 2: Adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) for associations between BMI (per 1-SD increase) and CCDs by age, sex, diabetic status, and hypertensive status

| Variable                  | Subgroup | \( n \) | OR     | 95% CI      | \( P \text{ for interaction} \) |
|---------------------------|----------|--------|--------|-------------|-------------------------------|
| Age (years)               | \( \leq 50 \) | 2,056 | 1.06   | 0.82–1.37   | 0.791                         |
|                           | \( >50 \)  | 1,886 | 1.18   | 1.05–1.33   |                               |
| Sex                       | Male     | 1,955 | 1.10   | 0.94–1.29   | 0.200                         |
|                           | Female   | 1,987 | 1.26   | 1.09–1.46   |                               |
| Diabetic status           | Yes      | 172   | 1.81   | 1.20–2.72   | 0.237                         |
|                           | No       | 3,770 | 1.10   | 0.99–1.23   |                               |
| Hypertension \( \geq 130/80 \) mm Hg | Yes   | 2,544 | 1.28   | 1.14–1.42   | <0.001                        |
|                           | No       | 1,398 | 0.73   | 0.55–0.99   |                               |
| Hypertension \( \geq 140/90 \) mm Hg | Yes | 934   | 1.17   | 1.01–1.34   | 0.575                         |
|                           | No       | 3,008 | 1.08   | 0.92–1.28   |                               |

Abbreviations: CCDs, cardiovascular and cerebrovascular diseases; BMI, body mass index. The values are presented as the odds ratios (ORs) and 95% confidence intervals (95% CIs); ORs were obtained after adjusting for age, sex, hypertensive status, alcohol use, smoking, and diabetic status.
We only found significant interaction by hypertension in the relationship between BMI and CCDs when hypertension was defined as having a blood pressure \( \geq 130/80 \text{ mm Hg} \), but not \( \geq 140/90 \text{ mm Hg} \). The underlying reasons for this finding are uncertain. However, there is in vitro evidence suggesting that there are interrelated mechanisms between high blood pressure, BMI, and CCDs [14,15,31,32]. As this is the first epidemiological study suggesting these interrelationships, our findings warrant further confirmation.

The interrelationships between hypertension, BMI, and CCDs are likely to be attributed to numerous mechanisms. First, adipokines are highly deregulated under obesity and may control cardiovascular homeostasis [33,34]. Adipose tissue can release free fatty acids (FFA) in the proximity and around the coronary arteries, modulating vascular responsiveness to vasoactive agents [35] and turning into an adverse lipotoxic, pro-thrombotic, and pro-inflammatory factor (IFNy) to overexpress chemotactic cytokines (i.e., MCP-1, IL-6) [33,36,37]. In addition, adipose tissue can discharge FFA into the bloodstream, disturbing vascular homeostasis and endothelial dysfunction, which leads to increased risk of CCDs [33,38]. Second, elevated blood pressure leads to systemic arteriole spasm by increasing the permeability of the vascular endothelium, prolonging the contact time of lipoproteins with the vascular wall, and reducing the endothelium-dependent vasodilation. The systemic arteriole spasm was suggested to increase risk of CCDs [39]. Third, blood pressure regulation is centered on endothelial function, which is regulated by the interaction of the renin–angiotensin–aldosterone system, adrenergic receptors, and metabolic reactions; these endothelial function-related mechanisms are also closely related to adipose tissue [40,41]. Furthermore, obesity-related FFA inhibits the sodium/potassium exchange pump and sodium-ATP pump, which increases smooth muscle tone, peripheral resistance, and blood pressure [42,43].

The present study’s findings have clinical implications at the population level. According to the latest ACC/AHA hypertension guidelines [18], we were able to screen more hypertensive patients compared to the previous standard (blood pressure \( \geq 140/90 \text{ mm Hg} \)). The advantage of using the new hypertension definition is that it will allow us to prevent adverse hypertension-related outcomes (i.e., CCDs) at an early stage.

There are several strengths for our study. First, we used a community-based population with random sampling methods. The possibility for generalizing our findings to the population is high. Second, this study had a high response and validity rate, further increasing the representativeness of the findings. Lastly, blood pressure for each participant was directly measured thrice at a stable and consistent condition. Antihypertension medications were also considered. All these factors ensured validity and reliability of hypertensive status.

Several limitations must be considered in the interpretation of our results. First, because of the cross-sectional study design, we cannot conclude a temporal relationship between hypertension and BMI with CCDs. Second, this study is conducted in a Shuncheng, Fushun, Liaoning, which is relatively a small area. Thus, the generalizability for our findings may be limited. Third, only some major CCD risk factors were considered in this study. Data for dietary intake, physical activity, and genetics were not included in this study, because they are not available. Potential residual confounding cannot be fully excluded.

In summary, there are interrelated relationships between BMI, CCDs, and hypertension. Furthermore, hypertension modifies the relationship between BMI and CCDs. Although BMI was independently associated with CCDs, this association was primarily limited to individuals with hypertension (\( \geq 130/80 \text{ mm Hg} \)). These results suggested that prevention efforts for CCDs among obese individuals may need to focus on individuals with a blood pressure \( \geq 130/80 \text{ mm Hg} \). Further studies are warranted to confirm our results.

**List of abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| ACC/AHA | The American College of Cardiology/American Heart Association |
| BMI | body mass index |
| CCDs | cardiovascular and cerebrovascular diseases |
| CDC | Centers for Disease Control |
| CHD | coronary heart disease |
| 95% CIs | 95% confidence intervals |
| DBP | diastolic blood pressure |
| FFA | free fatty acids |
| MI | myocardial infarction |
| ORs | odds ratios |
| RAAS | renin–angiotensin–aldosterone system |
| SBP | systolic blood pressure |
| SD | standard deviation |

**Acknowledgments:** We acknowledge the institutional review board at Fushun Center for Disease Prevention and Control (CDC) for approving this research.
**Funding:** This work has no funding body.

**Author contributions:** The authors made the following contributions: W. Q. and S. Y. analyzed the data. X. Z., S. X., Y. Z., B. K., B. L., Q. Z., and D. G. collected data. W. Q. drafted the article. S. Y., X. S., and A. M. V. reviewed the manuscript. All authors contributed to the study design. S. Y. managed the overall project. All the authors critically revised the article for important intellectual content and approved the final version of the manuscript.

**Conflict of interest:** The authors declare no potential conflict of interest.

**Data availability:** The data used in this study are owned and managed by the Fushun CDC. Because of ethical restrictions regarding individual privacy, data are available upon request. Data are available upon request from Fushun CDC. The authors did not have special access privileges and interested researchers can access the data in the same manner as the authors.

**References**

[1] Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K, et al. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circ Res. 2017;121(6):677–94.

[2] Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373(9667):929–40.

[3] Volpe M, Tocci G. Global cardiovascular risk management in primary prevention. Curr Vasc Pharmacol. 2012;10(6):709–11.

[4] Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–9.

[5] Benjamin EJ, Munter P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American heart association. Circulation. 2019;139(10):e56–66.

[6] Strazzullo P, D’Elia L, Cairella G, Garbagnati F, Cappuccio FP, Scalfi L. Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke. 2010;41(5):e418–26.

[7] Toyoda K, Ninomiya T. Stroke and cerebrovascular diseases in patients with chronic kidney disease. Lancet Neurol. 2014;13(8):823–33.

[8] Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: a report from the American heart association. Circulation. 2017;135(10):e146–603.

[9] Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083–96.

[10] Heianza Y, Kodama S, Arase Y, Hsieh SD, Yoshizawa S, Tsuji H, et al. Role of body mass index history in predicting risk of the development of hypertension in Japanese individuals: Toranomon hospital health management center study 18 (TOPICS 18). Hypertension. 2014;64(2):247–52.

[11] Zou ZY, Yang YD, Wang S, Dong B, Li XH, Ma J. The importance of blood lipids in the association between BMI and blood pressure among Chinese overweight and obese children. Br J Nutr. 2016;116(1):45–51.

[12] Chen Z, Smith M, Du H, Guo Y, Clarke R, Bian Z, et al. Blood pressure in relation to general and central adiposity among 5,000,000 adult Chinese men and women. Int J Epidemiol. 2015;44(4):1305–19.

[13] Bundy JD, He J. Hypertension and related cardiovascular disease burden in China. Ann Glob Health. 2016;82(2):227–33.

[14] Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. Lancet. 2014;383(9921):970–83.

[15] Bogers RP, Bemelmans WJ, Hoogenveen RT, Boshuizen HC, Woodward M, Knekt P, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 3,00,000 persons. Arch Intern Med. 2007;167(16):1720–8.

[16] He W, Li Q, Yang M, Jiao J, Ma X, Zhou Y, et al. Lower BMI cut-offs to define overweight and obesity in China. Obesity (Silver Spring, Md). 2015;23(3):684–91.

[17] Oakkar EE, Stevens J, Truesdale KP, Cai J. BMI and all-cause mortality among Chinese and Caucasians: the People’s Republic of China and the atherosclerosis risk in communities studies. Asia Pac J Clin Nutr. 2015;24(3):472–9.

[18] Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/ABC/ACP/MAGS/APHA/ASH/ASA/ACEP/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;71(19):e127–248.

[19] Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., et al. The Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2506–72.

[20] Yatsuya H, Matsunaga M, Li Y, Ota A. Risk factor of cardiovascular disease among older individuals. J Atheroscler Thromb. 2017;24(3):258–61.

[21] Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham heart study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014;383(9921):999–1008.

[22] Huxley R, Mendis S, Zheleznyakov E, Reddy S, Chan J. Body mass index, waist circumference and waist:hip ratio as
predictors of cardiovascular risk – a review of the literature. Eur J Clin Nutr. 2010;64(1):16–22.

[23] Sun W, Huang Y, Xian Y, Zhu S, Jia Z, Liu R, et al. Association of body mass index with mortality and functional outcome after acute ischemic stroke. Sci Rep. 2017;7(1):2507.

[24] Barry VW, Caputo JL, Kang M. The joint association of fitness and fatness on cardiovascular disease mortality: a meta-analysis. Prog Cardiovasc Dis. 2018;61(2):136–41.

[25] Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Nadeau M, Scarp J, et al. Alterations of plasma metabolite profiles related to adipose tissue distribution and cardiometabolic risk. Am J Physiol Endocrinol Metab. 2015;309(8):E736–46.

[26] Zhao D, Wang W, Liu J, Cheng J, Liu J, Qin LP. Association between body mass index and ten-year-accumulative-risk of hypertension. Zhonghua Liu Xing Bing Xue Za Zhi. 2009;30(5):435–8.

[27] Schütten MT, Houben AJ, de Leeuw PW, Stehouwer CD. The link between adipose tissue renin-angiotensin-aldosterone system signaling and obesity-associated hypertension. Physiology (Bethesda, Md). 2017;32(3):197–209.

[28] Urtamo A, Jyväkori SK, Kautiainen H, Pitkälä KH, Strandberg TE. Major cardiovascular disease (CVD) risk factors in midlife and extreme longevity. Aging Clin Exp Res. 2020;32(2):299–304.

[29] Kane AE, Howlett SE. Differences in cardiovascular aging in men and women. Adv Exp Med Biol. 2018;1065:389–411.

[30] Ortega-Loubon C, Fernández-Molina M, Singh G, Correa R. Obesity and its cardiovascular effects. Diabet Metab Res Rev. 2019;35(4):e3135.

[31] Corden B, Keenan NG, de Marvao AS, Dawes Tj, Deecares A, Diamond T, et al. Body fat is associated with reduced aortic stiffness until middle age. Hypertension. 2013;61(6):1322–7.

[32] Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, Thompson A, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377(9777):1085–95.

[33] González N, Moreno-Villegas Z, González-Bris A, Egido J, Lorenzo Ó. Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes. Cardiovasc Diabetol. 2017;16(1):44.

[34] Boulet MM, Chevrier G, Grenier-Larouche T, Pelletier M, Dayer JM, et al. Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis? Arterioscler Thromb Vasc Biol. 2005;25(12):2594–9.

[35] Henriët E, Juge-Aubry CE, Pernin A, Pache JC, Velebit V, Dayer JM, et al. Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis? Arterioscler Thromb Vasc Biol. 2005;25(12):2594–9.

[36] Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol. 2013;4:71.

[37] Aslanabadi N, Salehi R, Javadrashid A, Tarzammi M, Khodadad B, Enamzadeh E, et al. Epicardial and pericardial fat volume correlate with the severity of coronary artery stenosis. J Cardiovasc Thorac Res. 2014;6(4):235–9.

[38] Perticone F, Ceravolo R, Candigliota M, Ventura G, Iacopino S, Spinelli F, et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes. 2001;50(1):159–65.

[39] Yuan X, Braun T. Multimodal regulation of cardiac myocyte proliferation. Circ Res. 2017;121(3):293–309.

[40] Mu F, Harris HR, Rich-Edwards JW, Hankinson SE, Rimm EB, Spiegelman D, et al. A prospective study of inflammatory markers and risk of endometriosis. Am J Epidemiol. 2018;187(3):515–22.

[41] Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D’Ambrosia G, Arbique D, Vongpatanasin W, et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magnetic Reson Med. 2003;49(3):417–23.

[42] Bell BB, Rahmouni K. Leptin as a mediator of obesity-induced hypertension. Curr Obes Rep. 2016;5(4):397–404.

[43] Alpert MA, Omran J, Mehra A, Ardhanari S. Impact of obesity and weight loss on cardiac performance and morphology in adults. Prog Cardiovasc Dis. 2014;56(4):391–400.